What are the newest treatments for Lymphoma in 2026

Newest Lymphoma Treatments in 2026

I'm happy to provide an overview of the most current treatment approaches for lymphoma. Let me break down what's new and important to understand.

CAR T-Cell Therapy - Now Standard of Care

One of the most significant advances in lymphoma treatment is CAR T-cell therapy (chimeric antigen receptor T-cell therapy). This is a type of immunotherapy where doctors take your own immune cells, modify them in a laboratory to recognize and attack cancer cells, and then return them to your body.

What's important to know:

• According to recent FDA approvals and clinical evidence, anti-CD19 CAR T-cell therapy is now considered standard of care for patients with relapsed or refractory (R/R) aggressive non-Hodgkin's lymphoma (NHL) after 2 or more lines of prior treatment
• Three FDA-approved CAR T products are available: axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel
• These therapies have shown unprecedented response rates in high-risk patients
• CAR T-cell therapy has also been FDA-approved for specific lymphoma subtypes including Mantle Cell Lymphoma and Follicular Lymphoma

Molecular Residual Disease (MRD) Testing - Emerging Game-Changer

A newer development that's changing how doctors monitor lymphoma is MRD testing using circulating tumor DNA (ctDNA). This blood test detects remaining cancer cells after treatment before they become clinically visible.

Key points:

• According to the NCCN Guidelines for B-Cell Lymphomas (updated December 2024), MRD testing is now included in treatment guidance
• Tests like Foresight CLARITY Lymphoma can detect relapse approximately 200 days (6-7 months) earlier than traditional PET/CT imaging in DLBCL
• This allows doctors to identify molecular recurrence before symptoms appear and adjust treatment plans accordingly
• MRD testing is validated for: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, and Classic Hodgkin Lymphoma

Personalized Treatment Based on Biomarkers

According to NCCN Guidelines for Marginal Zone Lymphomas, treatment decisions increasingly depend on understanding specific genetic mutations in your cancer cells:

• Mutation testing looks for specific DNA changes in lymphoma cells that may respond to targeted therapies
• Some mutations can develop during treatment or cause resistance to certain drugs
• Understanding your specific biomarkers helps doctors select the most effective treatment approach for YOUR cancer

Imaging and Staging Advances

Modern imaging continues to improve:

• PET/CT scans remain standard for detecting cancer and monitoring response
• MRI scans are used in specific situations
• These imaging tests help guide treatment decisions and monitor how well treatment is working

Questions to Ask Your Oncology Team

Since treatment options vary significantly based on your specific lymphoma type, stage, and biomarkers, here are important questions:

1. What type and stage of lymphoma do I have? (This determines which treatments apply to me)
2. What biomarker or mutation testing has been done on my cancer cells? (This identifies targeted therapy options)
3. Am I a candidate for CAR T-cell therapy? (Especially important if you have aggressive lymphoma or relapsed disease)
4. Will MRD testing be part of my monitoring plan? (This can help catch recurrence earlier)
5. What are the clinical trials available for my specific situation? (New treatments are constantly being studied)

Important Resources

The Lymphoma Research Foundation (lymphoma.org) and Be the Match (bethematch.org) offer excellent patient resources for understanding treatment options and finding support.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

The specific treatments recommended for you will depend on your lymphoma subtype, stage, biomarkers, prior treatments, and overall health status—factors only your oncology team can fully evaluate.